Although the risks of several outcomes, for example, influenza and pneumonia, for CYP2C19 likely intermediate, intermediate and poor metabolizers are not statistically significant, they could be due to the limited sample size, and the risk estimates are higher compared to those among other types of metabolizers. The gene discussed is CYP2C19; the disease is pneumonia.